Autres langues Opus Genetics, Inc.

Actions

IRD

US67577R1023

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
4,650 ^USD	+4,26%		+1,53%	+131,34%

11/09	SANTÉ-Un collyre expérimental atténue les troubles de la vision nocturne chez les conducteurs	RE
10/09	Opus Genetics, Inc. : Chardan Research optimiste sur le dossier	ZM

Autres langues

21/09	Opus Genetics, Inc.(NasdaqCM:IRD) added to S&P Global BMI Index
11/09	HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers
09/09	Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of Opgx-Best1 and Successful Fda Type C Meeting with Potential Phase 3 Dosing in 2027
09/09	Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial
09/09	Opus Genetics Shares Reach 52-Week High on Clinical Trial, FDA Progress
09/09	Top Midday Gainers
09/09	Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial
09/09	Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
02/09	Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
19/08	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/08	Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
03/08	Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder
03/08	Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
03/08	Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease
09/07	Opus Genetics Provides Update On OPGx-BEST1 Program With Detailed Timeline For OPGx-BEST1 Results
09/07	Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
06/07	Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says
06/07	Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-Lca5 in Lca5-Associated Inherited Retinal Disease
06/07	Opus Genetics Reaches Alignment With US FDA on Phase 3 Trial of OPGx-LCA5 to Treat Retinal Disease
06/07	Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
29/06	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell Small Cap Comp Growth Benchmark
29/06	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 2500 Growth Benchmark
29/06	Opus Genetics, Inc.(NasdaqCM:IRD) added to Russell 2000 Index
29/06	Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes